Anthem Biosciences shares listed on the stock market today with strong momentum. The shares opened at ₹723.05 on NSE—a 27% gain over the IPO price of ₹570. On BSE, the stock listed at ₹723.10.
The IPO was a big hit, with subscriptions 64 times over, showing high investor demand. The company raised ₹3,395 crore in total, and ₹1,016 crore came from anchor investors. But even with a good listing, it was still a bit lower than the grey market expectation of 31% gain.
What’s Special About Anthem Biosciences?
Anthem is not just any pharma company. It’s a tech-based, end-to-end service provider in drug research and manufacturing. It handles everything—from discovery to delivery—for both small molecule and biologic drugs.
It works across CRO and CRDMO segments and has over 675 clients in 44 countries. What’s more? It owns India’s largest fermentation capacity at 182 kL.
Financials Look Strong
- Revenue is growing at 25–30% CAGR
- EBITDA margins are around 37%
- Return on capital employed (ROCE) is in the high teens
Also, this IPO was a pure Offer For Sale (OFS), which means no new shares were issued. So, there is no dilution, and the company starts fresh with no extra financial burden.
Also Read India Sees 108 IPOs Raising $4.6 Billion in First Half of 2025: EY Report
What Experts Say
Naren Agarwal from Wealth1 said Anthem is set to lead India’s biotech wave. Its strong business model and client list give it an edge. If earnings stay strong in Q2, the stock could move even higher.
Narendra Solanki from Anand Rathi feels the IPO was fairly priced. At a PE ratio of 70.6, based on FY25 estimates, it’s not cheap. But the solid margins and steady growth make it a good long-term play.
Should You Buy, Sell or Hold?
If you got shares during the IPO, holding may be the best move right now. The stock is backed by strong fundamentals. Long-term investors could benefit from the company’s leadership in biotech and global reach.
If you missed the IPO and are thinking of buying now, you might want to wait for a dip. Since it listed a bit lower than expected, it could see some short-term volatility.
For traders, profit booking at 25–30% gains could also be a smart exit if you’re looking for quick returns.
Anthem Biosciences has made a solid debut, but the real test begins now. If you’re in it for the long haul, its tech-first model and global partnerships look promising. But if you’re only here for a quick ride, watch the price closely.
Disclaimer:
This article is for informational purposes only and is not financial advice. Please consult a certified advisor before making investment decisions.
Also Read Snapdeal Parent AceVector Files Confidential IPO Draft with SEBI
